Healthcare / Drug Manufacturers - Specialty & GenericBSE
$347.20
+9.45 (+2.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.2B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.8B
P/E
69.6x
↑EV/EBITDA
27.5x
↑ROE
11.6%
↑Gross Margin
48.7%
↑Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
+35.8%
FCF margin
6.3%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.46B · net income $696.5M · FCF $470.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.46B | $7.46B | $7.70B | $6.80B | $7.13B |
| Net Income | $696.5M | $696.5M | $861.4M | $797.0M | $958.4M |
| EBITDA | $1.38B | $1.38B | $1.47B | $1.36B | $1.50B |
| EPS | 6.95 | 6.95 | 8.74 | 8.22 | 9.89 |
| Gross Margin | 48.7% | 48.7% | 48.1% | 49.8% | 40.7% |
| Operating Margin | 15.7% | 15.7% | 17.2% | 17.0% | 18.1% |
| Net Margin | 9.3% | 9.3% | 11.2% | 11.7% | 13.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.56 | 0.56 | 0.63 | 0.96 | 0.24 |
| Cash Flow | |||||
| Free Cash Flow | $470.4M | $470.4M | $-1.20B | $-2.14B | $187.9M |
| Returns | |||||
| ROE | 11.6% | 11.6% | 16.2% | 22.9% | 35.6% |
| Valuation | |||||
| P/E | 69.58 | 69.58 | 35.37 | 22.95 | 25.53 |
| EV/EBITDA | 27.50 | 27.50 | 22.91 | 15.74 | 16.69 |
| P/B | 5.79 | 5.79 | 5.72 | 5.26 | 9.09 |
| Growth & Yield | |||||
| Revenue Growth | -3.1% | -3.1% | 13.2% | -4.7% | — |
| EPS Growth | -20.5% | -20.5% | 6.3% | -16.9% | — |
| Dividend Yield | 0.0% | 0.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
64.3%
EPS terminal req.
$30.81
Spread vs growth
-84.8%
5Y implied EPS CAGR
39.9%
EPS terminal req.
$37.28
Spread vs growth
-60.5%
10Y implied EPS CAGR
24.1%
EPS terminal req.
$60.04
Spread vs growth
-44.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.9%
Start / end P/E
43.5x → 48.2x
EPS bridge
8.74 → 6.95
Residual
-2.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.